Why are Mesoblast shares racing 15% higher today?

Find out what caught investor interest.

Mesoblast Ltd (ASX: MSB) shares are rocketing higher into the green in morning trade on Thursday.

At the time of writing, the shares have jumped around 15% higher and are changing hands at $2.17 apiece. Today's increase means the shares have now climbed roughly 20% over the past week, recouping some of the losses incurred throughout the year.

But there is still some way to go. The shares are still down around 22% year to date and roughly 14% lower than 12 months ago.

The clinical-stage ASX biotech company has slowed through 2026 so far, likely off the back of an increase in investor caution around clinical timelines and some profit-taking after a late-2024 share price rally.

But it looks like the company's latest quarterly activities report, posted to the ASX ahead of the market open this morning, has already created a sharp turnaround in confidence.

Group of doctors celebrate by pumping fists in the air.

Image source: Getty Images

What did Mesoblast report today?

The company revealed its fiscal earnings for the quarter ended 30th of September.

Highlights include an 86% improvement in net operational cash spend to US$2.1 million, compared to US$14.9 million in the same quarter last year.

Mesoblast also confirmed it had US$99 million in cash as of the 30th of September.

Mesoblast's commercial flagship product, Ryoncil, is clearly gaining traction. The company reported net revenue from Ryoncil reached US$28 million for the quarter, which is 44% higher than the same period last year.

Mesoblast notes that September saw the highest number of monthly new patients starting Ryoncil, following an expected seasonal slowdown in July and August.

It looks like Mesoblast's rapid growth, at a time when it has also reduced its spending and improved its cash position, has been very well received by investors this morning. Many have rushed to snap up the shares.

The results were also impressive from an operational perspective. Mesoblast completed treatment of all 350 patients enrolled in its final large-scale Phase 3 human trial of its rexlemestrocel-L product for chronic low back pain.

The company also had a positive meeting with the US Food and Drug Administration (FDA) about their filing approach for its rexlemestrocel-L product to assist with end-stage heart failure in patients with a left ventricular assist device (LVAD).

What do the experts think of Mesoblast shares?

I expect that analysts and brokers will revise their target prices for Mesoblast shares in the coming days, following its quarterly update this morning.

But at the time of writing, expert sentiment is overwhelmingly bullish.

TradingView data shows that all seven analysts have a strong buy rating on the shares. The average $4.33 target price implies a potential upside of around 99%, at the time of writing, even after today's rally. 

Some are even more optimistic and think Mesoblast shares could jump around another 156% to $5.55 over the next 12 months.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »